Floatz logo

Zoladex

Hormone Receptor Positive, HER2-negative Neoplasms

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Hormone Receptor Positive, HER2-negative Neoplasms cohort.

Asset / SponsorPhaseRating
Epirubicin
BicycleTx Limited
Phase 1/2CCC
Zelenectide Pevedotin
BicycleTx Limited
Phase 1/2CCC
Cyclophosphamide
BicycleTx Limited
Phase 1/2CCC
Pembrolizumab
BicycleTx Limited
Phase 1/2CCC
FULVESTRANT
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
D

View all 10 →

Same molecule, other indications

Zoladex is also rated in:

HR+/HER2- Breast CancerDormant
BB
Indicative ·
71 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
69 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →